Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412 - PubMed (original) (raw)
Clinical Trial
Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412
Peter A Campochiaro et al. Invest Ophthalmol Vis Sci. 2004 Mar.
Abstract
Purpose: To evaluate the efficacy and safety of PKC412, an orally administered kinase inhibitor, in subjects with diabetic macular edema.
Methods: This was a randomized (1:1:1:1), multicenter, double-masked, parallel-group study in which subjects (n = 141) received placebo or PKC412 (50, 100, or 150 mg/d) for up to 3 months. Subjects were 18 to 85 years of age and had retinal thickening that met predefined criteria and best corrected visual acuity of 55 letters or more. Efficacy was based on changes in retinal thickening measured by grading of fundus photographs and optical coherence tomography (OCT) and changes in visual acuity.
Results: Grading of fundus photographs showed a statistically significant decrease in the area of greatest retinal thickening in patients receiving 150 mg/d of PKC412 (P = 0.032). OCT demonstrated that the two higher doses of PKC412 caused a significant decrease in thickening in the region of greatest thickening and in the fovea (P < or = 039), with response in the high-dose group significantly different from that in the placebo group (difference = -66.69 micro m [95.2% CI: -128.57 to -4.81]; P = 0.030). Retinal volume for all locations also showed a significant decrease from baseline in the 100- and 150-mg/d PKC412 groups (P < or = 004), and the 150-mg/kg group showed significantly less retinal volume than the placebo group at 3 months (difference = -0.46 mm(3) [95.2% CI: -0.86-0.06]; P = 0.019). There was a small (4.36 letters), but significant (P = 0.007), improvement in visual acuity at 3 months compared with baseline in the 100-mg/d PKC412 group. Gastrointestinal side effects (diarrhea, nausea, and vomiting) were the most common adverse events attributed to the drug. Dose-related effects were observed for tolerability, glycemic control, and liver toxicity.
Conclusions: Orally administered PKC412 at doses of 100 mg/d or higher may significantly reduce macular edema and improve visual acuity in diabetic subjects. However, concern regarding liver toxicity with systemic therapy makes local delivery an appealing approach.
Similar articles
- Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A. Haritoglou C, et al. Retina. 2006 Nov-Dec;26(9):999-1005. doi: 10.1097/01.iae.0000247165.38655.bf. Retina. 2006. PMID: 17151486 Clinical Trial. - Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C. Kook D, et al. Retina. 2008 Oct;28(8):1053-60. doi: 10.1097/IAE.0b013e318176de48. Retina. 2008. PMID: 18779710 - A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Callanan DG, Loewenstein A, Patel SS, Massin P, Corcóstegui B, Li XY, Jiao J, Hashad Y, Whitcup SM. Callanan DG, et al. Graefes Arch Clin Exp Ophthalmol. 2017 Mar;255(3):463-473. doi: 10.1007/s00417-016-3472-1. Epub 2016 Sep 8. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 27632215 Clinical Trial. - Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.
Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM; Ozurdex CHAMPLAIN Study Group. Boyer DS, et al. Retina. 2011 May;31(5):915-23. doi: 10.1097/IAE.0b013e318206d18c. Retina. 2011. PMID: 21487341 Clinical Trial. - Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
PKC-DRS2 Group; Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE. PKC-DRS2 Group, et al. Ophthalmology. 2006 Dec;113(12):2221-30. doi: 10.1016/j.ophtha.2006.07.032. Epub 2006 Sep 20. Ophthalmology. 2006. PMID: 16989901 Clinical Trial.
Cited by
- The role of protein kinase C in diabetic microvascular complications.
Pan D, Xu L, Guo M. Pan D, et al. Front Endocrinol (Lausanne). 2022 Aug 17;13:973058. doi: 10.3389/fendo.2022.973058. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36060954 Free PMC article. Review. - FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.
Acharya B, Saha D, Armstrong D, Lakkaniga NR, Frett B. Acharya B, et al. RSC Med Chem. 2022 May 23;13(7):798-816. doi: 10.1039/d2md00067a. eCollection 2022 Jul 20. RSC Med Chem. 2022. PMID: 35923716 Free PMC article. Review. - Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture.
Campochiaro PA. Campochiaro PA. Invest Ophthalmol Vis Sci. 2021 Nov 1;62(14):26. doi: 10.1167/iovs.62.14.26. Invest Ophthalmol Vis Sci. 2021. PMID: 34817536 Free PMC article. No abstract available. - A review of FLT3 inhibitors in acute myeloid leukemia.
Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. Zhao JC, et al. Blood Rev. 2022 Mar;52:100905. doi: 10.1016/j.blre.2021.100905. Epub 2021 Nov 3. Blood Rev. 2022. PMID: 34774343 Free PMC article. Review. - Non-invasive multimodal imaging of Diabetic Retinopathy: A survey on treatment methods and Nanotheranostics.
Sadasivam R, Packirisamy G, Shakya S, Goswami M. Sadasivam R, et al. Nanotheranostics. 2021 Jan 15;5(2):166-181. doi: 10.7150/ntno.56015. eCollection 2021. Nanotheranostics. 2021. PMID: 33564616 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous